Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2466
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications ; volume:21 ; number:1 ; day:17 ; month:7 ; year:2021 ; pages:1-14 ; date:12.2021
BMC pulmonary medicine ; 21, Heft 1 (17.7.2021), 1-14, 12.2021
- Creator
-
Kelly, Bryan T.
Thao, Viengneesee
Dempsey, Timothy M.
Sangaralingham, Lindsey R.
Payne, Stephanie R.
Teague, Taylor T.
Moua, Teng
Shah, Nilay D.
Limper, Andrew H.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12890-021-01607-2
- URN
-
urn:nbn:de:101:1-2021102100363915237759
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kelly, Bryan T.
- Thao, Viengneesee
- Dempsey, Timothy M.
- Sangaralingham, Lindsey R.
- Payne, Stephanie R.
- Teague, Taylor T.
- Moua, Teng
- Shah, Nilay D.
- Limper, Andrew H.
- SpringerLink (Online service)
Other Objects (12)
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
Treating insomnia with medications
Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series
Polypharmacy and potentially inappropriate medications among hospitalized older adults with COVID-19 in Malaysian tertiary hospitals
Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis
Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
Treating insomnia with medications
Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series
Polypharmacy and potentially inappropriate medications among hospitalized older adults with COVID-19 in Malaysian tertiary hospitals
Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis
Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
Treating insomnia with medications
Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series
Polypharmacy and potentially inappropriate medications among hospitalized older adults with COVID-19 in Malaysian tertiary hospitals
Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis
Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis